Grant of Options

RNS Number : 8456K
Immupharma PLC
12 July 2017
 

                                                                                                                                                                           12 July 2017

 

 

 

 

Grant of Options

 

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over 1,400,000 ordinary shares of 10p each ("Ordinary Shares") to certain of its non-executive Directors representing 1.06% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis. The exercise price for these options is 56.75p pence being the closing middle market share price on 11 July 2017. The options will vest after three years and are exercisable between three and ten years from the date of grant.   

 

The amount of options granted to non-executive Directors are summarised in the following table:

 

Director

Ordinary Shares under Option

Tim McCarthy

1,000,000

Franco di Muzio

200,000

Stephane Mery

200,000

 

Following this grant of all options on the above date, the total number of share options outstanding will be 8,233,850 representing 6.2% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.

 

Messrs McCarthy, di Muzio and Mery currently have the following interests in issued Ordinary Shares:

 

Director

Number of

Ordinary Shares

% of issued share capital

at 11 July 2017

Tim McCarthy

38,462

0.03%

Franco di Muzio

99,412

0.08%

Stephane Mery

21,490

0.02%

 

 

Following the grant of the options referred to above, Messrs McCarthy, di Muzio and Mery will have the following interests in options over the Company's Ordinary Shares:

 

Director

Number of Ordinary Shares under option

Exercise Price

Expiry Date

Tim McCarthy

500,000

1,000,000

 

43.88p

56.75p

02.06.2026

12.07.2027

Franco di Muzio

100,000

100,000

100,000

200,000

76.80p

86.50p

43.88p

56.75p

31.07.2017

04.02.2019

02.06.2026

12.07.2027

Stephane Mery

100,000

200,000

43.88p

56.75p

02.06.2026

12.07.2027

 

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Ends

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman


Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

Northland Capital Partners Limited (NOMAD & Broker)

Patrick Claridge, David Hignell, Jamie Spotswood, Corporate Finance

Rob Rees, Corporate Broking

+44 (0)20 3861 6625








 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHRTMLTMBABMMR

Companies

Immupharma (IMM)
UK 100

Latest directors dealings